Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Microba Life SciencesASX:MAP Debt-to-Equity is 0.08 as of Dec. 2025, which is 100% above its 10-year median of 0.04. The stock has 6 warning signs investors should review. Among 182 Medical Diagnostics & Research companies, Microba Life Sciences ranks better than 80.77% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Microba Life Sciences's Debt-to-Equity or its related term are showing as below:
ASX:MAP'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.04 Max: 0.1
Current: 0.08
During the past 4 years, the highest Debt-to-Equity Ratio of Microba Life Sciences was 0.10. The lowest was 0.03. And the median was 0.04.
ASX:MAP's Debt-to-Equity is ranked better than 80.77% of 182
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.33
vs ASX:MAP: 0.08
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Microba Life Sciences Debt-to-Equity Related Terms
Microba Life Sciences Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Microba Life Sciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:MAP vs TMO, DHR, IDXX: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, Microba Life Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Microba Life Sciences Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Microba Life Sciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Microba Life Sciences's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Microba Life Sciences (ASX:MAP) has a Debt-to-Equity of 0.08 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Microba Life Sciences and its competitors. This is 100% above median its historical median of 0.04. Over the past decade, Microba Life Sciences' Debt-to-Equity has ranged from 0.03 to 0.10. According to the industry distribution chart, Microba Life Sciences ranks #35 out of 182 companies in the Medical Diagnostics & Research industry, placing it in the top 19.2%.
Is Microba Life Sciences' Debt-to-Equity too high?
Microba Life Sciences' current Debt-to-Equity of 0.08 is 100% above median its 10-year median of 0.04. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 0.10. The Medical Diagnostics & Research industry median Debt-to-Equity is 0.33. Microba Life Sciences' value of 0.08 is 75.8% below this industry median. Based on the distribution chart, Microba Life Sciences ranks #35 out of 182 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Microba Life Sciences' Debt-to-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Microba Life Sciences ranks #35 out of 182 companies for Debt-to-Equity. This places Microba Life Sciences in the top 19% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.33. Microba Life Sciences' value of 0.08 is 75.8% below this benchmark. Historically, Microba Life Sciences' own Debt-to-Equity has ranged from 0.03 to 0.10 over the past decade. While the company's 10-year median is 0.04 vs. the industry median of 0.33, Microba Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.33, based on 182 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Microba Life Sciences's current Debt-to-Equity of 0.08 is 75.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Microba Life Sciences and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Microba Life Sciences's current Debt-to-Equity is 0.08, which is 100% above median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microba Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Microba Life Sciences (ASX:MAP) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.23, compared to a current price of A$0.05 — trading 79.1% below its estimated fair value. The current Debt-to-Equity is 0.08, which is 100% above median its 10-year median of 0.04 and 75.8% below the Medical Diagnostics & Research industry median of 0.33. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Microba Life Sciences (ASX:MAP), the current Debt-to-Equity is 0.08 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are: Testing Services and Supplements, which derive key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MAP has been successfully added to your 
